Building a Zika virus vaccine

Zika virus is a mosquito-borne flavivirus that is associated with a wide range of congenital abnormalities and neurological disorders. Currently, there are no vaccines or antiviral strategies approved for use in the prevention or treatment of Zika. As part of our pledge to support global health, ATCC has developed several novel Zika virus-like particle (Zika-VLP)–based vaccine candidates that are designed to elicit a specific antibody response and provide interstrain protection. In this webinar, we will discuss the development of these vaccine candidates and will provide data demonstrating their ability to induce a strong immune response and provide a high level of protection against Zika virus in murine animal models.

(*Required fields)

First Name*
Last Name*
Organization Name*
I agree to receive updates from ATCC and its local distributors. We will not share your information and solely use it to send relevant communications.*